NEWTOWN, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), and Trawsfynydd Therapeutics, Inc. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).
First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease.
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a strategic U.S. license agreement with a global pharmaceutical company is anticipated to be completed post-closing
Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer.
Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team
Proteomedix, a Swiss diagnostics company committed to advancing prostate cancer care, announced today that it entered into an agreement for Labcorp, a leading global life sciences company, to be the only laboratory to develop and commercialize the Proclarix® Prostate Specific Antigen (PSA) test in the U.S.
Prognos Health, the largest real-world integrated data marketplace, has announced that it has raised $23 million in growth equity co-led by Marshall Wace and Safeguard Scientifics, with participation from Cigna Ventures, Hikma Ventures, Hunt Holdings, Labcorp, Maywic, Merck Global Health Innovation Fund, and Red and Blue Ventures.
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced that it has completed a financing with BDC Capital and iGan Ventures. The funds are to support MolecuLight's continued global expansion to meet growing customer demand for its MolecuLight i:X® and DX™ devices.
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that SWK Holdings Corporation has provided $10M USD structured debt to support MolecuLight's global commercial expansion. SWK Holdings Corporation (Nasdaq: SWKH) is a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies through the creation of unique financing structures.
Following the VCN acquisition the company still has about $65M in cash and a rich and growing pipeline. SYN investors could enjoy potential 500% gains In 1H 2022.
Synthetic Biologics (NYSE:SYN) has added ~2.9% in the pre-market after announcing a definitive agreement to acquire VCN Biosciences, a privately owned clinical-stage immuno-oncology company based in Spain.
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced it has signed a definitive agreement to acquire VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) delivery to trigger tumor cell death and promote immune cell infiltration into tumors.
Municipal Finance & Services Corp. (MFSC), a company focused on government arbitrage and committed to helping local governments and their vendors streamline and digitize the payments process to expand local government participation opportunities for minority-owned, women-owned, veteran / disabled veteran-owned, and the underserved/emerging business sector announced the completion of an equity commitment of up to $5M from Sixth Borough Capital Management.
Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage cellular medicine company developing off-the-shelf allogeneic therapies derived from the postpartum human placenta, today announced the closing of a merger with GX Acquisition Corp. (“GXGX”) and provided a corporate update.
Celularity Inc., a Florham Park-based clinical stage biotechnology company, has signed a definitive merger agreement with GX Acquisition Corp. that will see it become a publicly traded entity, it announced Friday.
Cell therapy developer Celularity is raising a total of $372 million, announcing Friday a merger with a blank-check acquisition company and a separate financing from selling shares to institutional investors.
Israel-based smartphone urinalysis and wound-care startup Healthy.io is purchasing fellow home-diagnostics company Inui Health in a roughly $9 million cash deal, CNBC reports. The agreement also involves milestones that Inui Health will need to meet, and sees CEO Dr. Jaime Tenedorio take on a new role within Healthy.io's team.
For Chloe Alpert, one of the biggest surprises of starting her own company begins with a CT scanner and ends with a boat ride. Subscribe to the Crunchbase Daily Alpert is the CEO and co-founder of Medinas, a software-fueled marketplace for reusable medical equipment. The company resells equipment from medical centers to other places, and handles all aspects of the sale from the beginning inventory check to shipment and reinstallation.
Chloé Alpert, the CEO of Bay Area-based start-up Medinas Health, joins Cheddar fresh off winning $1 million at the WeWork Creator Awards Global Finals. She discusses how the new influx of capital will help her company continue to disrupt the healthcare industry, and what she learned from judges Ashton Kutcher, Diddy, and Gary Vaynerchuk.
Fifty-nine startups took the stage at Y Combinator’s Demo Day 2, and among the highlights were a company that helps developers manage in-app subscriptions; a service that lets you create animojis from real photos; and a surplus medical equipment-reselling platform.
Medinas Health, a San Francisco, CA-based marketplace for healthcare organizations to buy and sell surplus and short-date medical supplies and equipment, raised $1M in seed funding.
A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised an eye-watering $250 million for its work in cancer.
If you were to walk into any surplus medical supply donation center in the U.S., you would immediately notice how much stuff lines the walls. Perfectly usable items like adhesive dressings, bandages, syringes, and surgical masks sit waiting to be donated to remote healthcare clinics and hospitals around the world simply because they will expire in a matter of months—and in some cases, even years.
Forbes, Sound Ventures and Rough Draft Ventures (powered by General Catalyst) today announced that Medinas won the Forbes Global Change the World competition for young for-profit entrepreneurs as part of the 2017 Forbes Under 30 Summit, taking place October 1-4 in Boston.
LipoSeuticals, Inc. (LSI), a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of parenteral drug products based on its proprietary and novel drug delivery technology, announced today that it recently closed a financing round for an undisclosed amount led by Delos Capital, a Hong Kong based life sciences fund.
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors is not a registered broker-dealer, and Finalis Securities LLC and Tungsten Partners LLC d/b/a Tungsten Advisors are separate, unaffiliated entities.
www.tungstenadv.com is operated by Tungsten Partners LLC, a privately held Delaware Limited Liability Company. Tungsten Partners LLC provides strategic advisory services.
Business Continuity Plan | Privacy Policy | FINRA Broker Check
Securities are offered through Finalis Securities LLC Member FINRA/SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors and Finalis Securities LLC are separate, unaffiliated entities.
www.tungstenadv.com is operated by Tungsten Partners LLC, a privately held Delaware Limited Liability Company. Tungsten Partners LLC provides strategic advisory services.
Business Continuity Plan | Privacy Policy | FINRA Broker Check
